Physician profile
Robert Amato
NPI 1922340793
$2,837.85
in general payments reported to CMS, 2019-2025
16 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $20.94 · 2022: $120 · 2023: $429 · 2024: $297 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,748 · Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,748.00 |
| Food and Beverage | $846.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,748.00 | 2025 | Dupixent |
| Pfizer INC. | $367.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $279.71 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $64.13 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $58.44 | 2019-2023 | Farxiga |
| Kestra Medical Technology Services, INC. | $51.13 | 2024-2025 | Assure Wcd |
| Paratek Pharmaceuticals, INC. | $42.06 | 2023-2024 | Nuzyra |
| Mylan Specialty L.P. | $40.07 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.42 | 2023-2024 | |
| Kerecis Limited | $23.34 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Glaxosmithkline, LLC. | $22.25 | 2023 | Trelegy Ellipta |
| Abbvie INC. | $20.94 | 2021 | |
| Shire North American Group INC | $20.38 | 2019 | |
| Astellas Pharma US INC | $14.79 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.